India
· Delayed Price · Currency is INR Jubilant Pharmova Statistics
Total Valuation
NSE:JUBLPHARMA has a market cap or net worth of INR 143.72 billion. The enterprise value is 163.61 billion.
| Market Cap | 143.72B |
| Enterprise Value | 163.61B |
Important Dates
The next estimated earnings date is Friday, May 16, 2025.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | Aug 2, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | -0.30% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 64.51M |
Valuation Ratios
The trailing PE ratio is 22.91.
| PE Ratio | 22.91 |
| Forward PE | n/a |
| PS Ratio | 2.03 |
| PB Ratio | 2.42 |
| P/TBV Ratio | 6.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 26.09 |
| EV / Sales | 2.32 |
| EV / EBITDA | 15.06 |
| EV / EBIT | 21.54 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 2.92 |
| Debt / FCF | n/a |
| Interest Coverage | 2.98 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.04% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 13.08M |
| Profits Per Employee | 1.16M |
| Employee Count | 5,399 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.79% in the last 52 weeks. The beta is 1.26, so NSE:JUBLPHARMA's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +32.79% |
| 50-Day Moving Average | 916.93 |
| 200-Day Moving Average | 1,001.00 |
| Relative Strength Index (RSI) | 48.41 |
| Average Volume (20 Days) | 474,493 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JUBLPHARMA had revenue of INR 70.64 billion and earned 6.27 billion in profits. Earnings per share was 39.50.
| Revenue | 70.64B |
| Gross Profit | 46.35B |
| Operating Income | 7.30B |
| Pretax Income | 7.21B |
| Net Income | 6.27B |
| EBITDA | 9.99B |
| EBIT | 7.30B |
| Earnings Per Share (EPS) | 39.50 |
Balance Sheet
The company has 10.77 billion in cash and 30.80 billion in debt, giving a net cash position of -20.03 billion.
| Cash & Cash Equivalents | 10.77B |
| Total Debt | 30.80B |
| Net Cash | -20.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 59.27B |
| Book Value Per Share | 373.88 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 65.62%, with operating and profit margins of 10.33% and 8.88%.
| Gross Margin | 65.62% |
| Operating Margin | 10.33% |
| Pretax Margin | 10.20% |
| Profit Margin | 8.88% |
| EBITDA Margin | 14.14% |
| EBIT Margin | 10.33% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.55%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 0.55% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.13% |
| Shareholder Yield | 0.68% |
| Earnings Yield | 4.36% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.
| Last Split Date | Mar 17, 2006 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |